| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received March 2, 2007
Accepted on May 2, 2007
CLINICAL RESEARCH: Clinical Research |
,
,
,
Departments of *Nephrology,
Clinical Chemistry,
Surgery,
Immunohematology and Bloodtransfusion, and ||Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands
1 To whom correspondence should be addressed. E-mail: s.p.berger{at}lumc.nl.
| Abstract |
|---|
Simultaneous pancreas-kidney transplantation (SPKT) is the treatment of choice for patients with type 1 diabetes and renal failure. However, this procedure is characterized by a high rate of postoperative infections, acute rejection episodes, and cardiovascular mortality. The lectin pathway of complement activation contributes to cardiovascular disease in diabetes and may play an important role in inflammatory damage after organ transplantation. This study therefore sought to determine how mannose-binding lectin (MBL), a major recognition molecule of the lectin pathway of complement activation, influences outcome after SPKT. MBL serum levels were determined in 99 and MBL genotypes in 97 consecutive patients who received an SPKT from 1990 through 2000 and related to patient and graft survival. At 12 yr, cumulative death-censored kidney graft survival was 87.5% in patients with an MBL level <400 ng/ml and 74.8% in the group with MBL levels >400 ng/ml (P = 0.021). Pancreas graft survival was significantly better in patients with low MBL levels (P = 0.016). MBL levels >400 ng/ml were associated with a hazard ratio of 6.28 for patient death (95% confidence interval 1.8 to 20.3; P = 0.003). Accordingly, survival was significantly better in recipients with MBL gene polymorphisms associated with low MBL levels. These findings identify MBL as a potential risk factor for graft and patient survival in SPKT. It is hypothesized that MBL contributes to the pathogenesis of inflammation-induced vascular damage both in the transplanted organs and in the recipients native blood vessels.
This article has been cited by other articles:
![]() |
M. A. Kaunisto, L. Sjolind, R. Sallinen, K. Pettersson-Fernholm, M. Saraheimo, S. Frojdo, C. Forsblom, J. Fagerudd, T. K. Hansen, A. Flyvbjerg, et al. Elevated MBL Concentrations Are Not an Indication of Association Between the MBL2 Gene and Type 1 Diabetes or Diabetic Nephropathy Diabetes, July 1, 2009; 58(7): 1710 - 1714. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kato, M. Chmielewski, H. Honda, R. Pecoits-Filho, S. Matsuo, Y. Yuzawa, A. Tranaeus, P. Stenvinkel, and B. Lindholm Aspects of Immune Dysfunction in End-stage Renal Disease Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1526 - 1533. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Roos, M. R. Daha, J. van Pelt, and S. P. Berger Mannose-binding lectin and the kidney Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3370 - 3377. [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673